Mycobacterium: overview, biology, diseases and clinical significance

Distinctive characteristics

Mycobacteria possess a distinctive, lipid-rich outer envelope that differs from the typical Gram-positive or Gram-negative cell wall. This cell wall contains long-chain mycolic acids and other complex lipids, giving colonies a waxy, often opaque appearance and conferring resistance to many chemical stresses. Because of this composition they are classically described as acid-fast and are identified in the laboratory using Ziehl–Neelsen or fluorescent stains rather than routine Gram stain. Many species are strictly aerobic and require molecular oxygen for growth, although some tolerate low-oxygen (microaerophilic) conditions. Their growth rate is markedly slower than many common bacteria: while organisms such as E. coli may double in minutes, clinically important mycobacteria often take hours to days to replicate, and M. leprae grows extremely slowly and cannot be cultured on conventional laboratory media.

Classification, ecology and groups

For practical and clinical purposes mycobacteria are often divided into three broad categories: the M. tuberculosis complex (the main cause of tuberculosis), M. leprae (leprosy), and the heterogeneous collection of nontuberculous mycobacteria (NTM) found in the environment. NTM species range from harmless colonizers to opportunistic pathogens. Mycobacteria can colonize human and animal hosts without producing obvious or adverse clinical signs; latent or subclinical infection is particularly common with M. tuberculosis.

Clinical importance and management

Diseases caused by mycobacteria include pulmonary and extrapulmonary tuberculosis, leprosy, skin and soft tissue infections, and conditions such as the Buruli ulcer. Treatment is complicated by the organisms’ intrinsic impermeability and slow growth. First-line antitubercular therapy typically uses multiple agents to which most species were historically susceptible, though many strains have become resistant. Agents used in therapy include rifamycins, isoniazid, ethambutol and others; mycobacteria tend to be less affected by beta-lactams such as penicillin. Nontuberculous species vary in susceptibility; many are treated with macrolides or rifamycins, while surgical management is sometimes required. Immune suppression — for example in people treated for cancer or living with HIV — increases the risk of progressive disease. Public health control of tuberculosis also relies on vaccination (BCG), screening and combination drug regimens to limit the emergence of multidrug-resistant and extensively drug-resistant strains.

Laboratory diagnosis and resistance

Diagnosis combines microscopy (acid-fast stains), culture on specialized media, nucleic acid amplification tests and immunologic assays. Because many mycobacteria endure hostile conditions, they can survive exposure to acids, alkalis and detergents that inactivate other bacteria; exposure to alkalis and oxidative stresses often does not eliminate them. Components of innate immunity such as complement-mediated lysis are less effective against their waxy outer layers (complement resistance), and their impermeable surface contributes to reduced susceptibility to common antibiotics. Emergence of antibiotic-resistant mycobacterial strains is a major clinical and public health concern.

History, notable facts and practical notes

The name Mycobacterium reflects early observations: the Greek prefix myco- means fungus, a reference to colonies that sometimes resemble moulds in appearance. Historically, key discoveries include identification of the leprosy bacillus by Gerhard Armauer Hansen and the isolation of the tuberculosis bacillus by Robert Koch; these milestones established mycobacteria as significant human pathogens and prompted development of specific staining and culture methods. Environmentally many species are free-living, and while a large proportion of the global population has been exposed to M. tuberculosis, only a subset develop active disease. Clinicians and microbiologists must balance laboratory detection challenges, prolonged treatment courses and prevention strategies to manage infections effectively.

• Key laboratory features: acid-fastness, slow growth, lipid-rich cell wall.
• Major human pathogens: M. tuberculosis, M. leprae, and several NTM species.
• Common reservoirs: soil, water and dust; opportunistic infection in immunocompromised hosts.

For further general reading and resources see introductory materials on the genus and clinical guidelines available from specialized infectious disease sources and public health agencies. For practical laboratory protocols and up-to-date treatment recommendations consult recognized references and local clinical guidelines.